SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $57,000 | -46.7% | 12,896 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $107,000 | +37.2% | 13,227 | +18.6% | 0.00% | 0.0% |
| Q2 2018 | $78,000 | -50.9% | 11,153 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $159,000 | +57.4% | 11,153 | -3.0% | 0.00% | +100.0% |
| Q4 2017 | $101,000 | -35.3% | 11,500 | -13.5% | 0.00% | -50.0% |
| Q3 2017 | $156,000 | +0.6% | 13,300 | +19.8% | 0.00% | 0.0% |
| Q2 2017 | $155,000 | -4.9% | 11,100 | -6.7% | 0.00% | -33.3% |
| Q1 2017 | $163,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |